Mark A. Dickson, MD

Associate Attending Physician
Memorial Sloan Kettering Cancer Center

Associate Attending Physician
Clinical Director, Sarcoma Medical Oncology Service
Memorial Sloan Kettering Cancer Center

Harvard AB 1999
Columbia MD 2003
Weill Cornell / New York Hospital 2003-2006
MSKCC since 2006

Poster(s):

• (P 134) PHASE II STUDY OF RUCAPARIB AND NIVOLUMAB IN PATIENTS WITH LEIOMYOSARCOMA

• (P 156) MANAGEMENT OF ADVERSE EVENTS IN THE AMPECT TRIAL OF NAB-SIROLIMUS FOR THE TREATMENT OF ADVANCED MALIGNANT PECOMA

• (P 167) STUDY-END ANALYSIS FROM AMPECT, AN OPEN-LABEL, PHASE 2 REGISTRATION TRIAL OF PATIENTS WITH ADVANCED MALIGNANT PECOMA TREATED WITH nab-SIROLIMUS, SHOWING DURABILITY OF RESPONSE AND LONG-TERM SAFETY

• (P 307) ADOLESCENT AND YOUNG ADULT SARCOMA TREATMENT HARMONIZATION: AYA MAP FOR OSTEOSARCOMA